{
    "root": "65dafe3e-7450-46dd-932f-6fff7e4e58b6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ondansetron",
    "value": "20250325",
    "ingredients": [
        {
            "name": "ONDANSETRON HYDROCHLORIDE",
            "code": "NMH84OZK2B"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "ondansetron injection 5-ht 3 receptor antagonist indicated prevention : • nausea vomiting associated initial repeat courses emetogenic cancer chemotherapy . ( 1.1 ) • postoperative nausea and/or vomiting . ( 1.2 )",
    "contraindications": "prevention nausea vomiting associated initial repeat courses emetogenic cancer chemotherapy ( 2.1 ) : • dilution ondansetron injection 50 ml 5 % dextrose injection 0.9 % sodium chloride injection required adult pediatric patients . • adults pediatric patients 6 months age older : recommended 0.15 mg/kg per dose 3 doses ( maximum 16 mg per dose ) , infused intravenously 15 minutes . • administer first dose 30 minutes start chemotherapy subsequent doses 4 8 hours first dose . prevention postoperative nausea and/or vomiting ( 2.2 ) : • dilution ondansetron injection required adult pediatric patients . • full prescribing information recommended instructions adult pediatric patients 1 month age older . patients severe hepatic impairment ( 2.3 ) : • exceed total daily dose 8 mg .",
    "warningsAndPrecautions": "ondansetron injection , usp , 2 mg/ml , available follows : 2 ml single dose vial packaged 25s ( ndc 0641-6080-25 ) 20 ml multiple dose vial packaged individually ( ndc 0641-6286-01 ) product , including packaging components , made natural rubber latex . store 20°c 25°c ( 68°f 77°f ) [ usp controlled room temperature ] . protect light . report suspected , contact hikma pharmaceuticals usa inc. 1-877-845-0689 , fda 1-800-fda-1088 www.fda.gov/medwatch . product inquiry call 1-877-845-0689 .",
    "adverseReactions": "ondansetron injection contraindicated patients known hypersensitivity ( e.g . , anaphylaxis ) product components . anaphylactic reported patients taking ondansetron [ ( 6.2 ) ] . concomitant apomorphine ondansetron contraindicated based reports profound hypotension loss consciousness apomorphine administered ondansetron .",
    "indications_original": "Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: •   nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. ( 1.1 ) •   postoperative nausea and/or vomiting. ( 1.2 )",
    "contraindications_original": "Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy ( 2.1 ) : •   Dilution of Ondansetron Injection in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection is required before administration to adult and pediatric patients. •   Adults and pediatric patients 6 months of age and older: The recommended dosage is 0.15 mg/kg per dose for 3 doses (maximum of 16 mg per dose), infused intravenously over 15 minutes. •   Administer the first dose 30 minutes before the start of chemotherapy and subsequent doses 4 and 8 hours after the first dose. Prevention of Postoperative Nausea and/or Vomiting ( 2.2 ) : •   Dilution of Ondansetron Injection is not required before administration to adult and pediatric patients. •   See full prescribing information for the recommended dosage and administration instructions for adult and pediatric patients 1 month of age and older. Patients With Severe Hepatic Impairment ( 2.3 ) : •   Do not exceed a total daily dose of 8 mg.",
    "warningsAndPrecautions_original": "Ondansetron Injection, USP, 2 mg/mL, is available as follows:\n                  2 mL Single Dose Vial packaged in 25s (NDC 0641-6080-25)\n                  20 mL Multiple Dose Vial packaged individually (NDC 0641-6286-01)\n                  This product, including the packaging components, is not made with natural rubber latex.\n                  \n                     Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Protect from light.\n                  \n                  To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\n                  For Product Inquiry call 1-877-845-0689.",
    "adverseReactions_original": "Ondansetron Injection is contraindicated for patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. Anaphylactic reactions have been reported in patients taking ondansetron [see Adverse Reactions (6.2)].\n                  \n                  The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron."
}